UNSPSC 51433305: Hydralazine hydrochloride

This classification denotes an antihypertensive agent with the molecular formula C8H8N4.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier FD171B778Y, chemically known as 1 (2h)-phthalazinone, hydrazone, monohydrochloride but more generally known as hydralazine hydrochloride, which bears US NIH Compound Identifier 3637. European Medicines Agency schedules Hydralazine hydrochloride in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02553MIG.

Most nations, for tariff and trade purposes, schedule hydralazine hydrochloride under HS 29339990 and SITC 51577. As of Q4 2014, HYDRALAZINE HYDROCHLORIDE remains US FDA's Preferred Term for this commodity. Hydralazine hydrochloride bears US NLM identifiers UMLS ID C0699178 and NCI Concept Code C551. SMILES: C1CCC2C(C1)CNNC2NN.CL.

UNSPSC 51433305 Hydralazine hydrochloride is a Commodity code covering a specific injectable antihypertensive medication procured by state and local emergency medical services and health agency pharmacy programs. State and local governments buy this drug primarily through emergency medical services procurement for advanced life support protocols and through state health agency pharmacy benefit programs that source generic pharmaceuticals for distribution across public health facilities. Issuing bodies include municipal fire departments and rescue services, state health and human services commissions, and cooperative purchasing alliances representing multiple state and local entities. The work involves direct manufacturer or authorized wholesaler supply of FDA-compliant injectable medications meeting Good Manufacturing Practices certification and Drug Supply Chain Security Act compliance, with vendors responsible for maintaining minimum shelf life and expiration-date warranties, arranging rapid delivery and replacement logistics, and providing comprehensive safety documentation including Safety Data Sheets and accessibility conformance reports.

Recent activity spans Florida, Texas, Minnesota, and Oregon. The City of Tampa's Purchasing Department issued an IFB (Bid No. 26P00188) in April 2026 for Advanced Life Support Medications including hydralazine and related injectables for Tampa Fire Rescue, with bids due April 8, 2026 and an estimated contract value of $40,000 under a one-year term with renewal options; the solicitation included a 5 percent Small Local Business Enterprise bid discount and required OSHA-compliant Safety Data Sheets and WCAG 2.2 accessibility documentation. The Texas Health and Human Services Commission posted an RFI (No. HHS0017013) in April 2026 to gather vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, signaling potential future state-level procurement for direct manufacturer contracting outside traditional pharmacy benefit manager channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued an RFP in January 2026 for Generic Multi Source Pharmaceuticals and OTC Products with a March 26, 2026 response deadline and an effective date of July 1, 2026, requiring products to flow through AmerisourceBergen, Cardinal Health, and Morris & Dickson with mandatory compliance to cGMP, DSCSA, and one-year minimum expiration dates.